{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T09:37:03Z","timestamp":1789983423088,"version":"4.0.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T00:00:00Z","timestamp":1671148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T00:00:00Z","timestamp":1671148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100013669","name":"Ionis Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013669","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s40120-022-00414-z","type":"journal-article","created":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T15:03:21Z","timestamp":1671203001000},"page":"267-287","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen"],"prefix":"10.1007","volume":"12","author":[{"given":"Teresa","family":"Coelho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rcia","family":"Waddington Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Chao","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye\u015fim","family":"Parman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Wixner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Weiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio A.","family":"Barroso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel R.","family":"Dasgupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiangtung W.","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Viney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. James B.","family":"Dyck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian D.","family":"Gillmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Khella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morie A.","family":"Gertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Obici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Berk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,16]]},"reference":[{"issue":"6","key":"414_CR1","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1007\/s00415-019-09688-0","volume":"268","author":"D Adams","year":"2021","unstructured":"Adams D, Ando Y, Beir\u00e3o JM, et al. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. J Neurol. 2021;268(6):2109\u201322.","journal-title":"J Neurol"},{"issue":"1","key":"414_CR2","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s40120-021-00235-6","volume":"10","author":"T Coelho","year":"2021","unstructured":"Coelho T, Ando Y, Benson MD, et al. Design and rationale of the global phase 3 NEURO-TTRansform study of antisense oligonucleotide AKCEA-TTR-L(Rx) (ION-682884-CS3) in hereditary transthyretin-mediated amyloid polyneuropathy. Neurol Ther. 2021;10(1):375\u201389.","journal-title":"Neurol Ther."},{"issue":"1","key":"414_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/jns.12153","volume":"21","author":"I Concei\u00e7\u00e3o","year":"2016","unstructured":"Concei\u00e7\u00e3o I, Gonz\u00e1lez-Duarte A, Obici L, et al. \u201cRed-flag\u201d symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst. 2016;21(1):5\u20139.","journal-title":"J Peripher Nerv Syst"},{"issue":"5","key":"414_CR4","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/mus.26034","volume":"57","author":"HH Schmidt","year":"2018","unstructured":"Schmidt HH, Waddington-Cruz M, Botteman MF, et al. Estimating the global prevalence of transthyretin familial amyloid polyneuropathy. Muscle Nerve. 2018;57(5):829\u201337.","journal-title":"Muscle Nerve"},{"issue":"4","key":"414_CR5","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/mus.27023","volume":"62","author":"PJB Dyck","year":"2020","unstructured":"Dyck PJB, Coelho T, Waddington Cruz M, et al. Neuropathy symptom and change: Inotersen treatment of hereditary transthyretin amyloidosis. Muscle Nerve. 2020;62(4):509\u201315.","journal-title":"Muscle Nerve"},{"key":"414_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1750-1172-8-31","volume":"8","author":"Y Ando","year":"2013","unstructured":"Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8:31.","journal-title":"Orphanet J Rare Dis"},{"key":"414_CR7","unstructured":"Mutations in Transthyretin Gene (TTR): Mutations in Hereditary Amyloidosis; 2015. http:\/\/amyloidosismutations.com\/mut-attr.php. Accessed July 7, 2022."},{"issue":"2","key":"414_CR8","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","volume":"68","author":"MS Maurer","year":"2016","unstructured":"Maurer MS, Hanna M, Grogan M, et al. Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol. 2016;68(2):161\u201372.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"414_CR9","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1007\/s00415-013-7051-7","volume":"260","author":"T Coelho","year":"2013","unstructured":"Coelho T, Maia LF, da Silva AM, et al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol. 2013;260(11):2802\u201314.","journal-title":"J Neurol"},{"issue":"2","key":"414_CR10","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/mus.26515","volume":"60","author":"A Yarlas","year":"2019","unstructured":"Yarlas A, Gertz MA, Dasgupta NR, et al. Burden of hereditary transthyretin amyloidosis on quality of life. Muscle Nerve. 2019;60(2):169\u201375.","journal-title":"Muscle Nerve"},{"issue":"2","key":"414_CR11","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40120-018-0106-z","volume":"7","author":"M Stewart","year":"2018","unstructured":"Stewart M, Shaffer S, Murphy B, et al. Characterizing the high disease burden of transthyretin amyloidosis for patients and caregivers. Neurol Ther. 2018;7(2):349\u201364.","journal-title":"Neurol Ther."},{"issue":"1","key":"414_CR12","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/ehf2.13154","volume":"8","author":"NJ Viney","year":"2021","unstructured":"Viney NJ, Guo S, Tai LJ, et al. Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data. ESC Heart Fail. 2021;8(1):652\u201361.","journal-title":"ESC Heart Fail."},{"issue":"1","key":"414_CR13","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa1114248","volume":"367","author":"LA Inker","year":"2012","unstructured":"Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367(1):20\u20139.","journal-title":"N Engl J Med"},{"issue":"1","key":"414_CR14","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):22\u201331.","journal-title":"N Engl J Med"},{"issue":"11","key":"414_CR15","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S0895-4356(98)00081-X","volume":"51","author":"JE Ware Jr","year":"1998","unstructured":"Ware JE Jr, Gandek B. Overview of the SF-36 health survey and the international quality of life assessment (IQOLA) project. J Clin Epidemiol. 1998;51(11):903\u201312.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"414_CR16","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/jns5.12059","volume":"19","author":"EJ Vinik","year":"2014","unstructured":"Vinik EJ, Vinik AI, Paulson JF, et al. Norfolk QOL-DN: validation of a patient reported outcome measure in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst. 2014;19(2):104\u201314.","journal-title":"J Peripher Nerv Syst"},{"issue":"10","key":"414_CR17","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727\u201336.","journal-title":"Qual Life Res"},{"key":"414_CR18","unstructured":"EQ-5D-5L user guide. Version 3.0 Rotterdam, The Netherlands: EuroQol Research Foundation; 2019 [September 2019]. https:\/\/euroqol.org\/publications\/user-guides. Accessed July 19, 2022."},{"issue":"1","key":"414_CR19","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13023-019-1000-1","volume":"14","author":"M Waddington-Cruz","year":"2019","unstructured":"Waddington-Cruz M, Schmidt H, Botteman MF, et al. Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series. Orphanet J Rare Dis. 2019;14(1):34.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"414_CR20","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1590\/0004-282x20180156","volume":"77","author":"M Waddington Cruz","year":"2019","unstructured":"Waddington Cruz M, Pinto MV, Pinto LF, et al. Baseline disease characteristics in Brazilian patients enrolled in Transthyretin Amyloidosis Outcome Survey (THAOS). Arq Neuropsiquiatr. 2019;77(2):96\u2013100.","journal-title":"Arq Neuropsiquiatr"},{"issue":"2","key":"414_CR21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3109\/13506129.2015.1019610","volume":"22","author":"PL Swiecicki","year":"2015","unstructured":"Swiecicki PL, Zhen DB, Mauermann ML, et al. Hereditary ATTR amyloidosis: a single-institution experience with 266 patients. Amyloid. 2015;22(2):123\u201331.","journal-title":"Amyloid"},{"issue":"s2","key":"414_CR22","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.3233\/JND-150091","volume":"2","author":"A Mazzeo","year":"2015","unstructured":"Mazzeo A, Russo M, Di Bella G, et al. Transthyretin-related familial amyloid polyneuropathy (TTR-FAP): a single-center experience in Sicily, an Italian endemic area. J Neuromuscul Dis. 2015;2(s2):S39\u201348.","journal-title":"J Neuromuscul Dis."},{"issue":"3","key":"414_CR23","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1080\/13506129.2018.1503593","volume":"25","author":"M Waddington-Cruz","year":"2018","unstructured":"Waddington-Cruz M, Ackermann EJ, Polydefkis M, et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial. Amyloid. 2018;25(3):180\u20138.","journal-title":"Amyloid"},{"issue":"1","key":"414_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11\u201321.","journal-title":"N Engl J Med"},{"key":"414_CR25","doi-asserted-by":"crossref","unstructured":"Adams D, Tournev IL, Taylor MS, et al. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid. 2022:1\u20139.","DOI":"10.1080\/13506129.2022.2091985"},{"issue":"1","key":"414_CR26","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1185\/03007995.2012.754348","volume":"29","author":"T Coelho","year":"2013","unstructured":"Coelho T, Maurer MS, Suhr OB. THAOS\u2014the transthyretin amyloidosis outcomes survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin. 2013;29(1):63\u201376.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"414_CR27","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s00415-017-8640-7","volume":"265","author":"T Yamashita","year":"2018","unstructured":"Yamashita T, Ueda M, Misumi Y, et al. Genetic and clinical characteristics of hereditary transthyretin amyloidosis in endemic and non-endemic areas: experience from a single-referral center in Japan. J Neurol. 2018;265(1):134\u201340.","journal-title":"J Neurol"},{"issue":"3","key":"414_CR28","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.jfma.2019.08.027","volume":"119","author":"HJ Lai","year":"2020","unstructured":"Lai HJ, Huang KC, Liang YC, et al. Cardiac manifestations and prognostic implications of hereditary transthyretin amyloidosis associated with transthyretin Ala97Ser. J Formos Med Assoc. 2020;119(3):693\u2013700.","journal-title":"J Formos Med Assoc"},{"issue":"1","key":"414_CR29","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s12883-017-0957-4","volume":"17","author":"HC Hsu","year":"2017","unstructured":"Hsu HC, Liao MF, Hsu JL, et al. Phenotypic expressions of hereditary transthyretin Ala97Ser related amyloidosis (ATTR) in Taiwanese. BMC Neurol. 2017;17(1):178.","journal-title":"BMC Neurol"},{"issue":"1","key":"414_CR30","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12883-021-02243-3","volume":"21","author":"N Pasutharnchat","year":"2021","unstructured":"Pasutharnchat N, Taychargumpoo C, Vorasettakarnkij Y, Amornvit J. Ala97Ser transthyretin amyloidosis-associated polyneuropathy, clinical and neurophysiological profiles in a Thai cohort. BMC Neurol. 2021;21(1):206.","journal-title":"BMC Neurol"},{"issue":"21","key":"414_CR31","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1097\/CM9.0000000000001094","volume":"133","author":"L Liu","year":"2020","unstructured":"Liu L, Li XB, Hu ZM, Huang SX, Tang BS, Zhang RX. Clinical and genetic features of transthyretin-related familial amyloid polyneuropathy in China. Chin Med J (Engl). 2020;133(21):2616\u20138.","journal-title":"Chin Med J (Engl)"},{"issue":"10","key":"414_CR32","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.jchf.2021.05.005","volume":"9","author":"AG Caponetti","year":"2021","unstructured":"Caponetti AG, Rapezzi C, Gagliardi C, et al. Sex-related risk of cardiac involvement in hereditary transthyretin amyloidosis: insights from THAOS. JACC Heart Failure. 2021;9(10):736\u201346.","journal-title":"JACC Heart Failure."},{"key":"414_CR33","doi-asserted-by":"crossref","unstructured":"Russo M, Gentile L, Di Stefano V, et al. Use of drugs for ATTRv amyloidosis in the real world: how therapy is changing survival in a non-endemic area. Brain Sci. 2021;11(5):545.","DOI":"10.3390\/brainsci11050545"},{"issue":"3","key":"414_CR34","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/13506129.2022.2052838","volume":"29","author":"Y Ando","year":"2022","unstructured":"Ando Y, Adams D, Benson MD, et al. Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis. Amyloid. 2022;29(3):143\u201355.","journal-title":"Amyloid"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-022-00414-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-022-00414-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-022-00414-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T15:27:29Z","timestamp":1673537249000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-022-00414-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,16]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["414"],"URL":"https:\/\/doi.org\/10.1007\/s40120-022-00414-z","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,16]]},"assertion":[{"value":"25 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was sponsored by Ionis Pharmaceuticals, Inc., Carlsbad, CA, USA. Medical writing and editorial support were provided by Sandra Westra, PharmD, and Jessica D. Herr, PharmD, of Peloton Advantage, LLC, an OPEN Health company, and funded by Ionis Pharmaceuticals, Inc., Carlsbad, CA, USA. Ionis Pharmaceuticals, Inc., also provided funding for the journal\u2019s Rapid Service Fee.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors made substantial contributions to the conceptualization and design of the work and\/or the acquisition, analysis, and interpretation of the data. All authors contributed to the drafting and critical review of this manuscript before providing approval for submission of the final version. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Teresa Coelho: has received financial support to attend scientific meetings from Akcea, Ionis, Alnylam, Pfizer, and Biogen, and receives no personal speaker or consultant honoraria. M\u00e1rcia Waddington Cruz: has received advisory board and speaker honoraria and financial support for conference attendance from Akcea, Alnylam, Pfizer, and Sobi. Chi-Chao Chao: reports no conflicts of interest. Ye\u015fim Parman: has lectured for Alnylam and Pfizer. Jonas Wixner: has received advisory board and speaker honoraria and financial support for conference attendance from Akcea, Alnylam, and Pfizer. Markus Weiler: has received advisory board and speaker honoraria and financial support for conference attendance from Akcea, Alnylam, Pfizer, and Sobi. Fabio A. Barroso: has received advisory board and speaker honoraria and financial support for conference attendance from Alnylam, Pfizer, and PTC Therapeutics. Noel R. Dasgupta: has received advisory board honoraria from Ionis, Akcea, Alnylam, Pfizer, Eidos, and Intellia, and speaker honoraria from Akcea, Alnylam, and Pfizer. Shiangtung W. Jung: is employed by Ionis. Eugene Schneider: is employed by Ionis. Nicholas J. Viney: is employed by Ionis. P. James B. Dyck: reports no conflicts of interest. Yukio Ando: reports no conflicts of interest. Julian D. Gillmore: has served as an advisor for Alnylam, Ionis, Intellia, Eidos, Pfizer, and ATTRalus. Sami Khella: has served as a consultant to Alnylam, Ionis, Sobi, Pfizer, and Eidos. Morie A. Gertz: has received personal fees from Aptitude, Celgene, Ionis, Akcea, Janssen, Johnson & Johnson, Physicians Education Resource, Prothena, Research to Practice, and Sanofi; health grants and personal fees from Ashfield; financial support for meetings from Juno and Sorrento; fees for serving on a data safety monitoring board from AbbVie; fees for the development of educational materials from i3Health. Laura Obici: has received advisory board and speaker honoraria from Akcea, Alnylam, Pfizer, and Sobi. John L. Berk: has received honoraria for serving on advisory boards for Akcea, Ionis and Eidos, BridgeBio; scientific advisory boards for Corino, and received remotely, Intellia.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"Portions of the data in this manuscript have been presented at: the Peripheral Nerve Society, May 14\u201317, 2022 in Miami, Florida; the European Academy of Neurology, June 25\u201328, 2022 in Vienna, Austria; and the International Symposium on Amyloidosis, September 4\u20138, 2022.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Prior Presentation"}},{"value":"The protocol was approved by the institutional review board at the study sites or an independent ethics committee, and trial conduct complied with the Declaration of Helsinki of 1964 and its later amendments, and Good Clinical Practice guidelines. Written informed consent was obtained for all patients prior to enrollment.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethics Guidelines"}},{"value":"The datasets generated during and\/or analyzed during the current study are not publicly available and the study is ongoing.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}}]}}